Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
yahoo.com
finance
2022-06-02 20:30:00

Olema Pharmaceuticals, Inc.

SAN FRANCISCO, June 02, 2022 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. ('Olema,' 'Olema Oncology' or the 'Company,' Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women's cancers, today announced that the Company granted stock options to two new employees to purchase an aggregate of 25,400 shares of the Company's common stock, effective as of June 1, 2022. These awards were approved by the Compensation Committee of Olema's Board of Directors and granted under the Company's 2022 Inducement Plan, with a grant date of June 1, 2022, as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
